C-RAD Targets Profitable Growth as Demand for Advanced Radiotherapy Solutions Rises

C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an update.

C-RAD AB, a leader in surface tracking technology for radiotherapy, focuses on products and services that enhance treatment accuracy, patient safety and clinical efficiency in cancer care. With a growing installed base in roughly 60 countries and a strong share of its niche market, the company aims to leverage its technology and service portfolio to support better outcomes in oncology.

The annual report for 2025 highlights C-RAD’s clear growth and market strategy, emphasizing expansion of its service business, value-added products and sustainability initiatives. Management underscores that rising global demand for efficient, outcome‑improving cancer treatments positions C-RAD for continued profitable and sustainable growth, reinforcing its role as a key enabler in modern radiotherapy workflows.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK26.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

More about C-Rad AB Class B

C-RAD AB is a global medical technology company specializing in advanced surface tracking systems for cancer radiotherapy. Its solutions are designed to improve the precision and effectiveness of radiation treatments while streamlining clinical workflows, and the company holds an estimated 30% market share with more than 2,000 systems delivered across about 60 countries.

Average Trading Volume: 28,437

Technical Sentiment Signal: Sell

Current Market Cap: SEK908.3M

See more insights into CRAD.B stock on TipRanks’ Stock Analysis page.